

## Notice Required Under ASX Listing Rule 3.13.1

MELBOURNE, AUSTRALIA, 23 September 2024: Cleo Diagnostics Ltd (Company) (ASX: COV) advises that the 2024 Annual General Meeting of shareholders is scheduled to be held on Wednesday, 27 November 2024 at 11.00am (AEDT).

The full details of the Annual General Meeting will be provided in the Notice of Meeting which will be made available to all shareholders and released to ASX in due course.

Accordingly, for the purposes of ASX Listing Rule 3.13.1, the Company advises that the closing date for director nominations is 9 October 2024.

Released with the authority of the Board.



Ms Pauline Moffatt  
Company Secretary

**Cleo Diagnostics Ltd** ASX:COV

Level 2, 480 Collins Street, Melbourne, VIC, 3000  
ACN 655 717 169 **T** +61 3 9614 0600 **E** office@cleodx.com

Directors  
Chair and Non-Executive Director **Adrien Wing**  
Chief Executive Officer and Executive Director **Dr Richard Allman**  
Chief Scientific Officer and Executive Director **Dr Andrew Stephens**  
Non-Executive Director and Lead Medical Advisor **Professor Tom Jobling**  
Non-Executive Director **Lucinda Nolan**